Vitrian officials said the company closed a $50 million investment (with the ability to scale to $65 million) into AmplifyBio’s Manufacturing Enablement Center (AMEC) in New Albany, OH as a first step of a larger commitment to support biomanufacturing in Central Ohio. AmplifyBio is an advanced therapy CRO and CDMO.
Located in what many consider Central Ohio’s advanced manufacturing corridor, the 350,000 ft2 AMEC site is home to AmplifyBio’s multi-modality process development and quality control labs and GMP manufacturing suites.
“We are excited to make our first investment in Ohio and launch a wider partnership with AmplifyBio,” said Scott Nudelman, co-founder and managing principal at Vitrian. “We have been impressed by the creativity and progressive thinking of the AmplifyBio team and look forward to further collaborations.
“The infrastructure investment from state and local government, favorable workforce development environment, and support of important institutional anchors in the Columbus area aligns well with our investment and partnership thesis.”
“We chose to partner with Vitrian based on the alignment of our strategic goals for our manufacturing site, and we are hopeful this is the first of many things we can do together.” added J. Kelly Ganjei, CEO of AmplifyBio. “As we execute our strategy to enable flexible advanced therapy manufacturing and ancillary services, we believe Vitrian will be a great partner.”
Vitrian describes itself as the first fully-integrated company dedicated exclusively to providing end-to-end solutions for biomanufacturing and cGMP facilities. Its mission is to foster the next generation of drugs and therapies through facility real estate investment/development, improving the capitalization process, and building capacity for future growth through civic engagement and workforce development, according to a company spokesperson, who added that Vitrian is engaged in training/capacity building for the entry-level biomanufacturing workforce across its primary markets.
Its current engagements span modalities across advanced therapeutics, aseptic fill/finish, synthetic biology, and radiopharma with active projects in six plus U.S. markets.
